Ipatasertib
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | PO |
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C24H32ClN5O2 |
Molar mass | 458.00 g·mol−1 |
3D model (JSmol) | |
| |
|
Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase II trials for treatment of breast cancer.[1]
In vitro, ipatasertib showed activity against all three isoforms of Akt.[2]
References
- ^ Clinical trial number NCT02301988 for "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer" at ClinicalTrials.gov
- ^ Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. (April 2013). "Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models". Clinical Cancer Research. 19 (7): 1760–72. doi:10.1158/1078-0432.CCR-12-3072. PMID 23287563.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Experimental cancer drugs
- Protein kinase inhibitors
- Chloroarenes
- Piperazines
- Isopropylamino compounds
- Secondary alcohols